Davidson Investment Advisors Boosts Stake in Zoetis Inc. $ZTS

Posted by on Aug 30th, 2026

Davidson Investment Advisors raised its stake in shares of Zoetis Inc. (NYSE:ZTS – Free Report) by 107.8% during the second quarter, Holdings Channel.com reports. The institutional investor owned 111,868 shares of the company’s stock after buying an additional 58,044 shares during the period. Davidson Investment Advisors’ holdings in Zoetis were worth $8,039,000 at the end of the most recent reporting period.

Several other hedge funds also recently bought and sold shares of the stock. Prosperity Bancshares Inc acquired a new position in shares of Zoetis in the fourth quarter worth $25,000. Cassaday & Co Wealth Management LLC acquired a new stake in shares of Zoetis during the first quarter valued at $28,000. Elyxium Wealth LLC acquired a new stake in shares of Zoetis during the fourth quarter valued at $32,000. Root Financial Partners LLC increased its position in Zoetis by 66.5% during the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock worth $30,000 after purchasing an additional 103 shares in the last quarter. Finally, Wellington Grp LLC raised its stake in Zoetis by 6,675.0% in the 1st quarter. Wellington Grp LLC now owns 271 shares of the company’s stock valued at $32,000 after purchasing an additional 267 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Performance

NYSE ZTS opened at $77.45 on Friday. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84. Zoetis Inc. has a 1-year low of $71.00 and a 1-year high of $156.49. The firm has a market capitalization of $32.00 billion, a P/E ratio of 12.76, a P/E/G ratio of 1.80 and a beta of 0.74. The business’s 50-day simple moving average is $75.57 and its 200-day simple moving average is $95.62.

Zoetis (NYSE:ZTS – Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.85 by $0.02. The firm had revenue of $2.47 billion during the quarter, compared to the consensus estimate of $2.50 billion. Zoetis had a net margin of 27.49% and a return on equity of 74.89%. The company’s revenue was down .2% on a year-over-year basis. During the same quarter in the prior year, the company earned $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Equities analysts predict that Zoetis Inc. will post 6.2 EPS for the current year.

Analyst Ratings Changes

Several research firms have issued reports on ZTS. BNP Paribas Exane decreased their price target on shares of Zoetis from $146.00 to $110.00 and set an “outperform” rating on the stock in a research note on Tuesday, August 11th. Morgan Stanley set a $85.00 price objective on shares of Zoetis in a research report on Friday, August 7th. William Blair reissued a “market perform” rating on shares of Zoetis in a research note on Thursday, August 6th. Citigroup decreased their target price on shares of Zoetis from $112.00 to $96.00 and set a “buy” rating on the stock in a research report on Tuesday, August 11th. Finally, TD Cowen lowered their target price on shares of Zoetis from $104.00 to $94.00 and set a “buy” rating for the company in a research note on Tuesday. Eight equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $107.43.

Check Out Our Latest Research Report on ZTS

About Zoetis

(Free Report)

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

Featured Stories

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS – Free Report).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.